Article Text

other Versions

PDF
Rheumatoid arthritis (RA) patients treated with TNF-antagonists increase their participation in the work-force – potential for significant long-term indirect cost gains. Data from a population-based registry
  1. Jenny Augustsson (jenny.augustsson{at}ki.se)
  1. Dept of Medicine, Rheumatology Unit, Karolinska Institute, Sweden
    1. Martin Neovius (martin.neovius{at}ki.se)
    1. Dept of Medicine, Centre for Pharmacoepidemiology, Karolinska Institute, Sweden
      1. Cheryl Cullinane-Carli (cheryl.cullinane-carli{at}karolinska.se)
      1. Dept of Medicine, Rheumatology Unit, Karolinska Institute, Sweden
        1. Staffan Eksborg (staffan.eksborg{at}karolinska.se)
        1. Dept of Woman and Child Health, Childhood Cancer Research Unit, Karolinska Institute, Sweden
          1. Ronald F van Vollenhoven (ronald.van.vollenhoven{at}ki.se)
          1. Dept of Medicine, Rheumatology Unit, Karolinska Institute, Sweden

            Abstract

            Objective: To investigate the effect of TNF-antagonist treatment on work-force participation in rheumatoid arthritis (RA) patients.

            Methods: Data from the Stockholm anti-TNFα follow-up registry (STURE) were used in this observational study. RA patients (n=594) aged 18-55y, (mean±SD 40±9) followed for up to five years were included with hours worked/week as the main outcome measure. Analyses were performed unadjusted and adjusted for baseline age, disease duration, HAQ, DAS28 and pain score.

            Results: At baseline patients worked a mean 20h/week (SD 18). In unadjusted analyses, significant improvements in hours worked/week were observed in patients already at six months +2.4h (1.3 to 3.5; mean, 95% confidence interval (95%CI)) with further increases compared to baseline at the one-year (+4.0h, 2.4 to 5.6) and two-year follow-up (+6.3h, 4.2 to 8.4). The trajectory appeared to stabilise at the 3year (+6.3h, 3.6 to 8.9), 4year (+5.3h, 2.3 to 8.4) and 5year follow-up (+6.6h, 3.3 to 10.0). In a mixed piecewise linear regression model, adjusted for age, sex, baseline disease activity, function and pain, an improvement of +4.2h/week was estimated for the first year followed by an added improvement of +0.5h/week annually during the years thereafter. Over five years of treatment, the expected indirect cost gain corresponded to 40% of the annual anti-TNF drug cost in patients continuing treatment.

            Conclusion: Data from this population-based registry indicate that biologic therapy is associated with increases in work-force participation in a group typically expected to experience progressively deteriorating work ability. This could result in significant indirect cost benefits to society.

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.